US20180333357A1 - Nanoemulsions with anti-inflammatory activity - Google Patents
Nanoemulsions with anti-inflammatory activity Download PDFInfo
- Publication number
- US20180333357A1 US20180333357A1 US15/963,955 US201815963955A US2018333357A1 US 20180333357 A1 US20180333357 A1 US 20180333357A1 US 201815963955 A US201815963955 A US 201815963955A US 2018333357 A1 US2018333357 A1 US 2018333357A1
- Authority
- US
- United States
- Prior art keywords
- oil
- nanoemulsion
- water
- water nanoemulsion
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007908 nanoemulsion Substances 0.000 title claims abstract description 137
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 115
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 56
- 238000000034 method Methods 0.000 claims abstract description 41
- 239000004094 surface-active agent Substances 0.000 claims abstract description 23
- 239000000839 emulsion Substances 0.000 claims abstract description 20
- 229920000642 polymer Polymers 0.000 claims abstract description 14
- 239000003381 stabilizer Substances 0.000 claims abstract description 10
- 230000000087 stabilizing effect Effects 0.000 claims abstract description 10
- 239000008181 tonicity modifier Substances 0.000 claims abstract description 8
- 229920003169 water-soluble polymer Polymers 0.000 claims abstract description 8
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 71
- 206010013774 Dry eye Diseases 0.000 claims description 56
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 48
- 239000003921 oil Substances 0.000 claims description 43
- 235000019198 oils Nutrition 0.000 claims description 43
- 235000011187 glycerol Nutrition 0.000 claims description 24
- 239000004359 castor oil Substances 0.000 claims description 21
- 235000019438 castor oil Nutrition 0.000 claims description 21
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 239000012071 phase Substances 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 13
- 229940068968 polysorbate 80 Drugs 0.000 claims description 13
- 229920000053 polysorbate 80 Polymers 0.000 claims description 13
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 12
- 239000008346 aqueous phase Substances 0.000 claims description 11
- 239000003995 emulsifying agent Substances 0.000 claims description 8
- 235000019846 buffering salt Nutrition 0.000 claims description 7
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 229920005862 polyol Polymers 0.000 claims description 6
- 150000003077 polyols Chemical class 0.000 claims description 6
- 238000010186 staining Methods 0.000 claims description 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 5
- 239000005642 Oleic acid Substances 0.000 claims description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 5
- 239000004006 olive oil Substances 0.000 claims description 5
- 235000008390 olive oil Nutrition 0.000 claims description 5
- 235000005687 corn oil Nutrition 0.000 claims description 4
- 239000002285 corn oil Substances 0.000 claims description 4
- 150000002840 non-reducing disaccharides Chemical class 0.000 claims description 4
- 235000021313 oleic acid Nutrition 0.000 claims description 4
- 238000010008 shearing Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 229940057850 carbomer copolymer type a Drugs 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000000607 artificial tear Substances 0.000 abstract description 26
- 239000004480 active ingredient Substances 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 6
- 238000009472 formulation Methods 0.000 description 66
- 239000008186 active pharmaceutical agent Substances 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 17
- 239000000047 product Substances 0.000 description 15
- 235000014113 dietary fatty acids Nutrition 0.000 description 13
- 239000000194 fatty acid Substances 0.000 description 13
- 229930195729 fatty acid Natural products 0.000 description 13
- -1 fatty acid ester Chemical class 0.000 description 13
- JFOZKMSJYSPYLN-QHCPKHFHSA-N lifitegrast Chemical group CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C=2C(=C3CCN(CC3=CC=2Cl)C(=O)C=2C=C3OC=CC3=CC=2)Cl)C(O)=O)=C1 JFOZKMSJYSPYLN-QHCPKHFHSA-N 0.000 description 13
- 208000035475 disorder Diseases 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 239000003755 preservative agent Substances 0.000 description 11
- 208000022873 Ocular disease Diseases 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000007983 Tris buffer Substances 0.000 description 9
- 229960005381 lifitegrast Drugs 0.000 description 9
- 229920002125 Sokalan® Polymers 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- 206010065062 Meibomian gland dysfunction Diseases 0.000 description 7
- 230000002335 preservative effect Effects 0.000 description 7
- 239000001509 sodium citrate Substances 0.000 description 7
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000012929 tonicity agent Substances 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 125000002091 cationic group Chemical group 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 208000030533 eye disease Diseases 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 208000021386 Sjogren Syndrome Diseases 0.000 description 5
- 229960000686 benzalkonium chloride Drugs 0.000 description 5
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000004175 meibomian gland Anatomy 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 125000005250 alkyl acrylate group Chemical group 0.000 description 4
- 229920006037 cross link polymer Polymers 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 238000000265 homogenisation Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 206010023332 keratitis Diseases 0.000 description 4
- 210000004561 lacrimal apparatus Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000002997 ophthalmic solution Substances 0.000 description 4
- 229940054534 ophthalmic solution Drugs 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 229940023106 xiidra Drugs 0.000 description 4
- 229930105110 Cyclosporin A Natural products 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229940126534 drug product Drugs 0.000 description 3
- 210000000744 eyelid Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229960000502 poloxamer Drugs 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000011146 sterile filtration Methods 0.000 description 3
- 230000004489 tear production Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229920001664 tyloxapol Polymers 0.000 description 3
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 3
- 229960004224 tyloxapol Drugs 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000337 buffer salt Substances 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229960000228 cetalkonium chloride Drugs 0.000 description 2
- SXPWTBGAZSPLHA-UHFFFAOYSA-M cetalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SXPWTBGAZSPLHA-UHFFFAOYSA-M 0.000 description 2
- 229960002798 cetrimide Drugs 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 210000002175 goblet cell Anatomy 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 229960004716 idoxuridine Drugs 0.000 description 2
- 238000013339 in-process testing Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 description 2
- 229940023103 lifitegrast ophthalmic solution Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003346 palm kernel oil Substances 0.000 description 2
- 235000019865 palm kernel oil Nutrition 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 238000012371 Aseptic Filling Methods 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000029147 Collagen-vascular disease Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 239000001879 Curdlan Substances 0.000 description 1
- 229920002558 Curdlan Polymers 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 206010011841 Dacryoadenitis acquired Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 208000029728 Eyelid disease Diseases 0.000 description 1
- 206010069200 Eyelid injury Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010052143 Ocular discomfort Diseases 0.000 description 1
- 206010072139 Ocular rosacea Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 101150044878 US18 gene Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- FXAGBTBXSJBNMD-UHFFFAOYSA-N acetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FXAGBTBXSJBNMD-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 201000005668 blepharoconjunctivitis Diseases 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- WYEMLYFITZORAB-UHFFFAOYSA-N boscalid Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1NC(=O)C1=CC=CN=C1Cl WYEMLYFITZORAB-UHFFFAOYSA-N 0.000 description 1
- AZDOLIXTFBPILY-UHFFFAOYSA-N butanedioic acid;dihydrate Chemical compound O.O.OC(=O)CCC(O)=O AZDOLIXTFBPILY-UHFFFAOYSA-N 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 229940075508 carbomer homopolymer type b Drugs 0.000 description 1
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 201000000009 conjunctivochalasis Diseases 0.000 description 1
- 239000000882 contact lens solution Substances 0.000 description 1
- 206010011005 corneal dystrophy Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000019316 curdlan Nutrition 0.000 description 1
- 229940078035 curdlan Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 201000004400 dacryoadenitis Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002638 denervation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical class CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008378 epithelial damage Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 229920006242 ethylene acrylic acid copolymer Polymers 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000001936 exophthalmos Diseases 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 206010023365 keratopathy Diseases 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000000133 nasal decongestant Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 125000005430 oxychloro group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920005606 polypropylene copolymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 208000009169 relapsing polychondritis Diseases 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940053174 restasis Drugs 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- UUJLHYCIMQOUKC-UHFFFAOYSA-N trimethyl-[oxo(trimethylsilylperoxy)silyl]peroxysilane Chemical compound C[Si](C)(C)OO[Si](=O)OO[Si](C)(C)C UUJLHYCIMQOUKC-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Definitions
- the present invention relates to a sterile-filtered nanoemulsion having oil globules with a median size (Dv50) of about 100 nm or less, such as in the range of from about 40 to about 80 nm, and having an anti-inflammatory activity even in the absence of an active ingredient in the formulation.
- the present invention also relates to method of making the nanoemulsion and to the use of the nanoemulsion for topical application for a number of purposes in particular as an artificial tear.
- oil-in-water-type lipid emulsions e.g., nanoemulsions
- lipid emulsions e.g., nanoemulsions
- dry eye disease is the most actively investigated area.
- DED dry eye disease
- Tear replacement with ocular lubricants is traditionally considered a mainstay of DED therapy and there are numerous topical formulations available.
- Over-the-counter (OTC) products are often termed “artificial tears” which, as their name suggests, attempt to replace and/or supplement the natural tear film (TF).
- Typical treatments for dry eye syndrome include (i) instillation of artificial tears for tear supplementation and stimulation and (ii) the use of anti-inflammatory drugs to reduce ocular surface inflammation.
- current dry eye treatment involves topical application of artificial tear products/lubricants, tear retention management, stimulation of tear secretion, topical application of antibiotics (e.g., erythromycin or bacitracin ointments), oral administration of tetracyclines (e.g., tetracycline, doxycycline, or minocycline), application of anti-inflammatory compounds (cyclosporin) and corticosteroids.
- antibiotics e.g., erythromycin or bacitracin ointments
- tetracyclines e.g., tetracycline, doxycycline, or minocycline
- anti-inflammatory compounds cyclosporin
- corticosteroids corticosteroids
- Cationorm® a cationic nanoemulsion has been reported to enhance TF stability in vivo. See Georgieve et al., 2017, Int. J. Mol. Sci., 18:1558. Such cationic emulsions were observed to have an inherent benefit on the ocular surface in terms of reduced symptoms of ocular surface even in the absence of an active ingredient. The success of the CN was attributed to the interaction between the positively charged formulation and negatively charged corneal cells.
- ophthalmic emulsion drug product was Restasis (Allergan), a preservative-free anionic emulsion of cyclosporine A (CsA) at 0.05% indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation.
- CsA cyclosporine A
- Other emulsion-based eye drops available on the market are artificial tears Refresh Endura (Allergan), Soothe (Bausch & Lomb), etc.
- Another product for treating dry eye syndrome is lifitegrast (commercially available as Xiidra® ophthalmic solution 5%, Shire US Inc., Lexington, Mass.).
- Lifitegrast (chemical name: N- ⁇ [2-(1-Benzofuran-6-ylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro6-isoquinolinyl]carbonyl ⁇ -3-(methylsulfonyl)-L-phenylalanine) ophthalmic solution 5.0% has been reported to improve symptoms of ocular discomfort and eye dryness compared with placebo when administered twice daily (Sheppard et al., Ophthalmology, 2014, 121(2), pp. 475483).
- Ophthalmic products especially multidose products typically require a preservative to prevent microbial growth.
- concentration of a preservative in an ophthalmic product should be a compromise between preservative efficacy and toxicity.
- An alternative to the preservative use could be to subject the product to sterilization process so the product is sterile. It is known in the art from Lallemand et al., 2012, J Drug Deliv., 2012:1-16) that (i) a sterilizing filtration is not possible for emulsions as it uses a filter with 0.22 ⁇ m size pores that can clog during filtration and (ii) aseptic processes are too expensive. The remaining option was heat sterilization which has its own limitations.
- cationic agents are benzalkonium chloride, cetalkonium chloride, cetylpyridinium chloride, cetrimide and benzethonium chloride.
- these cationic agents are all known preservative or antibacterial compounds.
- nanoemulsions even without any active pharmaceutical ingredient (“API”) in them have anti-inflammatory properties on topical application to mammals thereby making it possible to obtain ophthalmic compositions without any API's but exhibiting all the advantages of known ophthalmic API formulations, such as those described above, without their disadvantages.
- the nanoemulsion formulations of the invention do not include any cations.
- the nanoemulsion formulations of the invention are neutral, meaning there is no anion or cation in the nanoemulsion. Without being bound by any theory, it is believed that the nanoemulsion formulation of the invention provides observed clinical activity primarily via a lipid-lipid interaction.
- the present invention relates to an oil-in-water nanoemulsion having oil globules with a median size (Dv50) of about 100 nm or less.
- the oil globules have a median size (Dv50) ranging from about 20 to about 80 nm.
- the oil globules have a median size (Dv50) ranging from about 40 to about 60 nm.
- the oil-in-water nanoemulsion contains an oil, and at least one or more of emulsion stabilizing polymers, a water-soluble polymer, a surfactant, a tonicity modifier or stabilizer.
- the nanoemulsion is a sterile-filtered nanoemulsion and is optionally preservative-free.
- the nanoemulsion even in the absence of an active ingredient, has ameliorative effects comprising anti-inflammatory activity on the ocular surface as determined by an improved corneal fluorescein staining (CFS) or CFS score compared to a therapeutic pharmaceutical composition containing lifitegrast.
- CFS corneal fluorescein staining
- an oil-in-water nanoemulsion comprises oil globules with a median size (Dv50) of about 100 nm or less.
- said nanoemulsion is a sterile-filtered nanoemulsion.
- the oil-in-water nanoemulsion consists essentially of an oil, an emulsion stabilizing polymer, a water soluble polymer, a surfactant, a tonicity modifier or stabilizer, a buffer, water, or a combination thereof.
- the oil in the emulsion is selected from castor oil, corn oil, olive oil or oleic acid, sesame oil, soybean oil, cottonseed oil, peanut oil, safflower oil, sunflower oil, palm oil, palm kernel oil, and canola oil or a combination thereof.
- the oil is castor oil.
- Preferred surfactant is polysorbate 80, and Pemulen® used as an emulsifier.
- Tonicity modifier or stabilizer is selected from a polyol, a non-reducing disaccharide, and a combination thereof.
- the oil-in-water nanoemulsion contains glycerin, a polymeric emulsifier (e.g., Acrylates/C 10-30 Alkyl Acrylate Cross-Polymer or Pemulen®), castor oil, a surfactant (e.g., polysorbate 80) and a buffering salt (e.g., sodium citrate dehydrate), and has a pH in the range of from about pH 5 to about pH 8.
- glycerin e.g., Acrylates/C 10-30 Alkyl Acrylate Cross-Polymer or Pemulen®
- castor oil e.g., castor oil
- a surfactant e.g., polysorbate 80
- a buffering salt e.g., sodium citrate dehydrate
- glycerin is present at a concentration of about 2.2% w/w
- the polymeric emulsifier is present at a concentration of about 0.05% w/w
- castor oil is present at a concentration of about 1.25% w/w
- the surfactant is present at a concentration of about 1% w/w
- the buffering salt is present at a concentration of about 0.15% w/w.
- Sufficient quantity of pH adjusting solutions are preferably added to prepare final nanoemulsion formulation. This final formulation is sterilized preferably by sterile filtration.
- the oil-in-water nanoemulsion is part of a vehicle for topically delivering a cosmetically, dermatologically or ophthalmologically active pharmaceutical agent.
- the present invention relates to a method of preparing the oil-in-water nanoemulsion described above.
- the method entails, among other steps, mixing the aqueous phase and the oil phase with vigorous stirring at a temperature ranging from about 55° C. to about 65° C., high shear mixing of the aqueous phase and the oil phase using homogenization method at a temperature ranging from about 55 to about 65° C. to realize a homogenized mixture.
- the homogenizing of the mixture is conducted at 3000 to 15000 rpm under high shear.
- the homogenized mixture is further subjected to high pressure preferably through a microfluidization method. Subjecting the homogenized mixture to a further high pressure is preferably carried out at a temperature ranging from about 55 to about 65° C. and at a pressure ranging from about 20000 to about 30000 psi.
- the present invention relates to a method of treating ocular surface disorders.
- Treating” or “treatment” of an ocular disorder includes: (1) preventing the disease, i.e., causing the clinical symptoms of the disease not to develop in a subject that may be exposed to or predisposed to the ocular disorder but does not yet experience or display symptoms of the ocular disorder; (2) inhibiting, arresting, ameliorating, or reducing the development of the ocular disorder or its clinical symptoms; or (3) relieving the ocular disorder or the symptoms of ocular disorder, i.e., causing regression of the ocular disorder or its clinical symptoms.
- the method involves administering an effective amount of the oil-in-water nanoemulsion of the present invention (i.e., “NanoE” or “ONETM”) topically to an eye of a subject (e.g., a human) in need of such a treatment.
- a subject e.g., a human
- the ocular surface disorder is a dry eye syndrome.
- the present invention relates to an oil-in-water nanoemulsion that is sterile-filterable.
- the nanoemulsion is preferably preservative-free.
- the nanoemulsion formulation of the invention can be prepared by a process involving mixing the aqueous phase and the oil phase with vigorous stirring typically at a temperature ranging from about 55 to about 65° C., homogenizing the mixture typically at a temperature ranging from about 55 to about 65° C. at 3000-15000 rpm and subjecting the homogenized mixture to high pressure shearing typically at a pressure ranging from about 20000 to about 30000 psi to provide the oil-in-water nanoemulsion of the invention.
- the oil-in-water nanoemulsion so realized can optionally be filtered using a 0.22 ⁇ m filter.
- the oil globules in nanoemulsion formulations of the invention have a median size (Dv50) ranging from about 20 to about 80 nm, and often ranging from about 40 to about 60 nm.
- Dv50 median size
- the sterile filtered nanoemulsion even in the absence of an active ingredient has therapeutic or ameliorative effects such as anti-inflammatory activity particularly on the ocular surface as determined by an improved corneal fluorescein staining (CFS).
- CFS corneal fluorescein staining
- the nanoemulsion formulations of the invention has anti-inflammatory activity similar to or better than a therapeutic pharmaceutical composition containing lifitegrast.
- active pharmaceutical ingredient and “active ingredient” are used interchangeably herein and refers to a drug or a physiologically active compound approved or as recognized by the Food and Drug Administration (“FDA”) or a compound recognized by one skilled in the art as being an active ingredient, see for example, en.wikipedia.org/wiki/Active_ingredient.
- FDA Food and Drug Administration
- the nanoemulsion formulations of the invention do not include any art recognized active ingredient.
- an artificial tear composition containing the oil-in-water nanoemulsion of the present invention and method of use of such artificial tears are provided.
- the oil-in-water nanoemulsion by itself is used as an artificial tear in which instance the artificial tears of the invention consist of the oil-in-water nanoemulsion of the present invention.
- the artificial tear composition of the invention can also consist essentially of the oil-in-water nanoemulsion of the present invention, i.e., it necessarily includes the oil-in-water nanoemulsion of the present invention, and is open to other components or ingredients (exclusive of any active pharmaceutical ingredients) that do not materially affect the basic and novel properties of the artificial tear composition of the invention.
- the artificial tear composition containing the oil-in-water nanoemulsion of the present invention or consisting of or consisting essentially of the oil-in-water nanoemulsion is used in a process for treating the symptoms of ocular surface disorders such as dry eye or from contact lens use.
- the method involves administering topically to an eye of a human subject in need of such a treatment an effective amount of the artificial tear containing, consisting of or consisting essentially of the oil-in-water nanoemulsion of the present invention.
- FIG. 1 is a graph showing Particle Size Distribution (PSD) of nanoemulsion measured using Mastersizer 3000 instrument (Malvern, UK).
- FIG. 2A shows images depicting representative corneal fluorescein staining (CFS) scores from the mouse dry-eye disease model in the three different groups from left to right as follows: (A) untreated; (B) NanoE nanoemulsion formulation (NanoE) only; and (C) Xiidra® (lifitegrast ophthalmic solution) 5% lifitegrast.
- CFS corneal fluorescein staining
- FIG. 2B is a histogram showing data related to the effect of placebo nanoemulsion against corneal epithelial damage in different groups as described in FIG. 2A . Data are presented as median ⁇ interquartile range.
- NanoE nanoemulsions of the invention
- ONETM nanoemulsions of the invention
- a nanoemulsion preferably an oil-in-water nanoemulsion with an oil phase dispersed in an aqueous phase, having an anti-inflammatory activity is provided.
- the nanoemulsions of the present invention are free of active pharmaceutical ingredient(s).
- active pharmaceutical ingredient is well known to one skilled in the art and is defined as any substance or mixture of substances intended to be used in the manufacture of a drug product and that, when used in the production of a drug, becomes an active ingredient in the drug product.
- the nanoemulsion of the present invention can be used as a topical ophthalmic formulation. In some embodiments, the nanoemulsion of the present invention is used as an artificial tear composition.
- the formulation necessarily contains an oil or a fatty acid ester.
- a fatty acid ester has the meaning commonly understood in the art, being an ester formed between an alcohol and a fatty acid.
- Exemplary fatty acid esters that are useful in formulations of the invention include, but are not limited to, triglyceride esters commonly known as vegetable oils, mono and diglyceride esters of fatty acids, fatty acid methyl esters, as well as other fatty acid esters that are known to one skilled in the art. It should be appreciated the fatty acid ester can be a mixture of several chemical compounds or an essentially pure compound. Typically, the fatty acid ester is a vegetable oil.
- vegetable oils that can be used include, but are not limited to, castor oil, corn oil, olive oil, oleic acid, sesame oil, soybean oil, cottonseed oil, peanut oil, safflower oil, sunflower oil, palm oil, palm kernel oil, and canola oil.
- the formulation contains castor oil, corn oil, olive oil, oleic acid or a combination of these components. It is particularly preferred that the fatty acid ester is castor oil.
- the oil phase can also contain fatty substances other than the oils indicated above, such as fatty alcohols, for example, stearyl, cetyl and behenyl alcohols, fatty acids, for example stearic, palmitic and behenic acids, oils of fluorinated type, waxes, gums and their mixtures.
- fatty alcohols for example, stearyl, cetyl and behenyl alcohols
- fatty acids for example stearic, palmitic and behenic acids
- oils of fluorinated type waxes, gums and their mixtures.
- the formulation can contain a pharmaceutically acceptable excipient including an emulsion stabilizing polymer, a surfactant, a water-soluble polymer, a tonicity modifier or a stabilizer selected from the group consisting of a polyol, a non-reducing disaccharide, and a combination thereof, buffering salts, and pH adjusting acid/base solutions.
- emulsion stabilizing polymers generally contain hydrophilic groups such as cellulose, sugars, ethylene oxide, hydroxide, carboxylic acids or other polyelectrolytes. Without being bound by any theory, it is believed that these polymers help to stabilize emulsions.
- emulsion stabilizing polymers useful in this invention include, but are not limited to, carbomers, Pemulen®, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, povidone, polyethylene glycol and a mixture of two or more thereof.
- Pemulen® (B.F. Goodrich, Cleveland, Ohio) is used as the polymeric emulsifier and/or nanoemulsion stabilizer.
- Pemulen® are Acrylates/C 10-30 Alkyl Acrylate Cross-Polymers.
- the water-soluble polymer can be any of polyacrylamides, polyacrylic acids or copolymers of polyacrylic acid, polyethylene oxides, guars, hydroxyethyl celluloses, polyvinyl alcohols or mixtures thereof.
- the water-soluble polymer is nonionic, that is to say neutral.
- the water-soluble nonionic polymer is present in a nanoemulsion thickening effective amount.
- the formulation of this invention further contains a surfactant.
- a surfactant is used to help facilitate the formation of the emulsion and improve its stability. Any type of surfactant can be used including, anionic, amphoteric, zwitterionic, nonionic, as well as a mixture of two or more thereof.
- the formulation of the invention contains an anionic or a nonionic surfactant.
- Exemplary nonionic surfactants include, but are not limited to, polysorbates, poloxamers, alcohol ethoxylates, ethylene glycol-propylene glycol block copolymers, fatty acid amides, alkylphenol ethoxylates, phospholipids, and two or mixture thereof.
- the surfactant is Polysorbate 80.
- the formulation of the present invention is preferably free of any cationic surfactant or contains surfactants other than cationic surfactants.
- the formulation contains surfactants that are nonionic.
- the nanoemulsion of the present invention containing nano-size globules contains castor oil, a surfactant-polysorbate 80, and an emulsifier-Pemulen TR2 and a tonicity agent-glycerine.
- Preferred formulation has the nano-size globules that are neutral at formulation pH (pH range of from about pH 5 to about pH 8), preferably at physiological pH (e.g., pH 7.4) without any significant positive or negative surface charges.
- the amount of surfactant in the nanoemulsion of the invention can range, for example, from about 0.1 to about 40 mg (i.e., 0.01% to 4% by weight) and preferably from about 0.5% to about 1% by weight with respect to the total weight of the nanoemulsion. These ranges include all specific values and subranges therebetween, such as 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 and 1.0%.
- a tonicity agent (tonicity-adjusting agent) is used to adjust the composition of the formulation to the desired isotonic range.
- the tonicity-adjusting agent can be a polyol or a disaccharide including non-reducing disaccharides.
- Such tonicity agents are known to one skilled in the art, and include, but are not limited to, glycerin, mannitol, sorbitol, trehalose, xylitol, sodium chloride, and other electrolytes.
- the tonicity agent is glycerin.
- gum and/or resin can be included in the formulations of the invention, including for example, sodium polyacrylate, cellulose ether, calcium alginate, carboxyvinyl polymer, ethylene-acrylic acid copolymer, vinyl pyrrolidone polymer, vinyl alcohol-vinyl pyrrolidone copolymer, nitrogen-substituted acrylamide polymer, polyacrylamide, cationic polymer such as cationic guar gum, dimethylacrylic ammonium polymer, acrylic acidmethacrylic acid copolymer, polyoxyethylene-polypropylene copolymer, polyvinyl alcohol, pullulan, agar, gelatine, chitosan, polysaccharide from tamarindo seed, xanthan gum, carageenan, high-methoxyl pectin, low-methoxyl pectin, guar gum, acacia gum, microcrystalline cellulose, arabinogalactan, karaya gum, tragacanth
- the formulations of the present invention are directed to artificial tear compositions containing combinations components but without any exogenously supplied active pharmaceutical ingredients in them (without regard to the use of transitional phrases such as “comprising” in claiming the invention herein) whereby an oil or a fatty acid ester, one or more nonionic surfactants and/or at least one excipient selected from polysorbate 80, an emulsion stabilizing polymer (e.g., Acrylates/C 10-30 Alkyl Acrylate Cross-Polymer or) Pemulen®, a polyol or a combination thereof confer the desired properties of relief from ocular disorders including those from contact lens use.
- an oil or a fatty acid ester one or more nonionic surfactants and/or at least one excipient selected from polysorbate 80
- an emulsion stabilizing polymer e.g., Acrylates/C 10-30 Alkyl Acrylate Cross-Polymer or
- Pemulen® e.g., a polyol or a
- the present invention is based, in part, on the surprising discovery that nanoemulsion of the present invention without any added active pharmaceutical ingredients can be used as artificial tears as a first-line therapy for ocular surface disorders such as dry eye or from contact lens use.
- ocular surface disorders such as dry eye or from contact lens use.
- the artificial tears containing nanoemulsion of the present invention improve or ameliorate the symptoms of ocular surface disorders by lubricating the ocular surface to create an evaporative tear shield that can stabilize the aqueous and lipid layers of the tear film and/or by increasing tear volume.
- Artificial tear compositions of the present invention also modestly confer anti-inflammatory activity on the ocular surface.
- the net effect of the relief provided by the artificial tear compositions of the present invention is at least as effective as, if not greater than, that provided by prescription medications such as Xiidra® ophthalmic solution 5% made by Shire US Inc., Lexington, Mass.
- Artificial tears can be formulated containing the oil-in-water nanoemulsion of the present invention. Accordingly, an artificial tear composition containing, consisting essentially of or consisting of the oil-in-water nanoemulsion of the present invention is used in a method for improving or ameliorating the symptoms of ocular surface disorders such as dry eye or from contact lens use.
- the invention provides methods of preparing the formulations of the present invention.
- the formulation is a nanoemulsion.
- the manufacturing process involves phase mixing of the aqueous phase and the oil phase.
- the mixture is preferably stirred at 100-200 rpm or higher for several minutes to hours.
- the samples are subjected to high shear mixing under homogenization.
- the shearing preferably ranges from 3000 to 15000 rpm and at 55 to 65° C.
- the high shear mixing is carried out at 3000-15000 rpm for 5-15 min depending on the manufacturing scale.
- High shear mixing is carried out to realize or obtain globules in the size range of ⁇ 10 micron (or ⁇ ), preferably ⁇ 7 micron, more often ⁇ 5 micron.
- the emulsion is put through a high-pressure microfluidization by passing the mixture through the high-pressure microfluidizer, preferably at a pressure higher than 20000 psi, at an ambient temperature of 45° C.-65° C.
- the high-pressure homogenization is carried out at a pressure ranging from 20000 to 30000 psi.
- Dv 50 globule mean size
- MMD Mass Median Diameter
- the viscosity can be in the range of 1-10 cP or cps when measured at ambient temperature (e.g., 25° C. or 32° C. or lower).
- the viscosity can be measured by any of a number of viscometers known in the art such as, for example, Brookfield viscometer (e.g., Model-DV2TLVCJ) and Spindle (e.g., CP-52) at 20 rpm.
- Brookfield viscometer e.g., Model-DV2TLVCJ
- Spindle e.g., CP-52
- formulations or nanoemulsions of the present invention are sterilized by filtering through a 0.22 ⁇ m filter (i.e., sterile-filtered) unless otherwise stated as sterilized by other means such as, for example, by autoclaving at about 121° C., or by gamma or e-beam irradiation, or by using antimicrobials or preservatives, etc.
- a 0.22 ⁇ m filter i.e., sterile-filtered
- a method of preparing the oil-in-water nanoemulsion can include mixing the aqueous phase and the oil phase with vigorous stirring at a temperature ranging from 55 to 65° C., homogenizing the mixture at a temperature ranging from 55 to 65° C. at 3000-15000 rpm under high shear and a further high pressure shearing using a microfluidizer at a much higher pressure which can range preferably from 20000 to 30000 psi.
- the step of homogenizing the mixture is preferably carried out at 3000-15000 rpm under high shear.
- nanoemulsion with its various components is as follows: surfactant such as Polysorbate 80 at about 0.02%-2% by weight or poloxamer/tyloxapol at about 0.1% and 0.25% by weight; carbomer copolymer (type A or type B) about 0.05% by weight; tonicity agent (glycerine or includes glycerine about 2.2% by weight; citrate/tris buffer of pH 6.0-8.0, sodium EDTA in the amount of about 0.02% or less by weight; an oil (e.g., castor oil) in the amount of about 1.25% by weight.
- surfactant such as Polysorbate 80 at about 0.02%-2% by weight or poloxamer/tyloxapol at about 0.1% and 0.25% by weight
- carbomer copolymer type A or type B
- tonicity agent glycerine or includes glycerine about 2.2% by weight
- citrate/tris buffer of pH 6.0-8.0, sodium EDTA in the amount of about 0.02% or
- the oil for the oil phase is a medium chain triglyceride in the range from 0.5-4%, typically at about 2%.
- all water-soluble components can be added and heated (about 60-70° C.) to make water the phase with buffer.
- a lipophilic solution is prepared using a lipophilic solvent (e.g., castor oil) and heating to about 60-70° C.
- the nanoemulsion is formed by rapid addition of lipophilic solution into water phase followed by high shear mixing.
- the final solution is sterilized via 0.22 micron filter. Alternatively, sterilization can also be done by autoclaving at about 121° C. for 20 min. Alternatively, sterilization can also be done by gamma or e beam irradiation.
- the sterilized nanoemulsion is filled into single dose disposable tubes by BFS technology or the like or into multi-dose container/closure systems (further described elsewhere herein).
- the formulation can be used topically, for caring for cosmetic, dermatological or ophthalmological conditions.
- this and other compositions described throughout the disclosure herein can be used for treating an eye disorder (e.g., dry eye syndrome) or alleviating the symptoms of the eye disorder or as an artificial tear composition.
- This particular formulation includes carbomer homopolymer type B in an amount ranging from about 0.2% to about 0.6%, by weight typically in an amount of about 0.4% or about 0.25%, and/or carbomer homopolymer type C in an amount ranging from about 0.4 to about 5% typically in an amount of about 4% or about 2.5%, and/or polycarbophil in an amount ranging from about 0.2% to about 0.5% typically in an amount of about 0.4% or about 0.2%; glycerin in an amount ranging from about 0.5% to about 1% typically in an amount of about 0.9%; optionally, benzalkonium chloride in an amount ranging from about 0.003% to about 0.01% typically in an amount of about 0.007%; edetate sodium in an amount ranging from about 0.03% to about 0.07% typically in an amount of about 0.05%; sodium chloride in an amount of up to about 0.09%, typically in an amount of about 0.06% or q.s
- the formulations of the present invention are preferably preservative-free unless stated otherwise.
- a “preservative” is a substance or a chemical that is added to products such as pharmaceutical and dermatological products and cosmetics and many other products in an attempt to prevent decomposition by microbial growth or by undesirable chemical changes.
- the term “preservative-free” used in connection with the nanoemulsions of the present invention refers to the formulations free of preservatives including benzalkonium chloride, cetalkonium chloride, cetylpyridinium chloride, cetrimide and benzethonium chloride and such other known preservatives.
- the formulation can be used topically, for caring for cosmetic, dermatological or ophthalmological conditions. Preferably, it can be used for treating an eye disorder (e.g., dry eye syndrome) or alleviating the symptoms of the eye disorder or as an artificial tear composition.
- a surfactant such as Polysorbate 80 at about 0.02%-2% by weight or carbomer copolymer (type A or type B) about 0.05% by weight
- tonicity agent glycerine or includes glycerine about 2.2% by weight
- sodium citrate and tris buffer of pH 6.0-8.0, sodium EDTA in the amount of about 0.02% or less by weight
- an oil e.g., castor oil in the amount of about 1.25% by weight.
- a surfactant such as Polysorbate 80 at about 0.02%-2% by weight
- carbomer copolymer type A or type B
- tonicity agent glycerin or includes glycerin about 2.2% by weight
- sodium citrate and tris buffer of pH 6.0-8.0 an oil (e.g., castor oil) in the amount of about 1.25% by weight, and acid/base solution to adjust the pH.
- Yet another example of a formulation with its various components is as follows: Carbopol 971 at about 0.1% to 0.4% by weight, poloxamer/tyloxapol at about 0.1% and 0.3% by weight; tonicity agent (glycerin or includes glycerin about 1% to 3% by weight; sodium citrate and tris buffer of pH 6.0-8.0; sodium EDTA in the amount of about 0.02% or less by weight.
- Still another example of a formulation with its various components is as follows: povidone at about 0.6% by weight, poloxamer/tyloxapol at about 0.1% and 0.25% by weight; tonicity agent (glycerine or includes glycerine about 1 to 3% by weight; sodium citrate and tris buffer of pH 6.0-8.0; sodium EDTA in the amount of about 0.02% or less by weight.
- the oil-in-water nanoemulsion contains glycerin, a polymeric emulsifier (e.g., Acrylates/C 10-30 Alkyl Acrylate Cross-Polymer or Pemulen®), castor oil, a surfactant (e.g., polysorbate 80) and a buffering salt (e.g., sodium citrate dehydrate), and has a pH of 5 to 8.
- a polymeric emulsifier e.g., Acrylates/C 10-30 Alkyl Acrylate Cross-Polymer or Pemulen®
- castor oil e.g., castor oil
- a surfactant e.g., polysorbate 80
- a buffering salt e.g., sodium citrate dehydrate
- glycerin is present at a concentration of about 2.2% w/w
- the polymeric emulsifier is present at a concentration of about 0.05% w/w
- castor oil is present at a concentration of about 1.25% w/w
- the surfactant is present at a concentration of about 1% w/w
- the buffering salt is present at a concentration of about 0.15% w/w.
- a small amount of Tris base (at about 0.03% w/w) can be present.
- the pH of the nanoemulsion can be adjusted using preferably HCl 0.1N and/or NaOH 0.1N as required. Water for injection q.s. is added.
- One particular nanoemulsion formulation composition is shown in Table 1 below.
- composition of the invention Ingredient Range per g Per g Other substitutes Function Castor Oil 5-100 mg 12.5 mg Olive oil, Oleic acid, etc. Oil Phase Polysorbate 0.1 to 40 mg 10 mg Polysorbate-20, A component to both help 80 Poloxamer 188 facilitate the formation of the heterogeneous mixture and improve its stability.
- Pemulen TR-2 0.1 to 2 mg 0.5 mg N/A Emulsion Stabilizer Glycerin 0-100 mg 22 mg Trehalose, sorbitol, Tonicity-Adjusting Agent mannitol, xylitol Sodium 0-20 mg 1.47 mg Phosphate, tris, histidine, Maintain pH Citrate acetate, succinate Dihydrate Tris Base 0-15 mg 1 mg Maintain pH Preservative Optional Optional benzalkonium chloride For multidose and nonsterile (BAK), stabilized products oxychloro complex (Purite) Base for pH pH 5 to 8 Maintain pH Acid for pH pH 5 to 8 Maintain pH Water for q.s. Vehicle Injection
- nanoemulsion formulations can be monitored. For example, the formulations are allowed to stand for a period of time (e.g., 6 months) at 20 to 25° C., and the heterogeneity sizes are measured. The heterogeneity sizes, within experimental error, should be identical at end of the test period to those measured right after the nanoemulsion is prepared thereby suggesting that there is no significant coalescence of the heterogeneity. Such results demonstrate that the nanoemulsion formulations so prepared have superior physical stability.
- a nanoemulsion formulation of the present invention can be a finished dosage form that does not contain an active ingredient.
- the dosage form of the invention is eye drops of the nanoemulsion formulations.
- the formulations of the present invention can be packaged in various package forms known in the field of topical ophthalmic.
- the formulations can be packaged in sterile single-use (unit dose) or multi-dose vials, preservative-free.
- the formulation is packaged in sterile, preservative-free single-use packs or vials or containers (i.e., the unit dose vials).
- Each vial for example as small as a 0.9 mL, may be made of low-density polyethylene so as to contain a small quantity of the formulation, e.g., 0.1-0.4 mL for a single use.
- a small quantity of the formulation e.g., 0.1-0.4 mL for a single use.
- multiple vials in the form of a set of 30 vials, 60 vials and so on can be packaged in a tray with a lid, for example, a polypropylene tray with an aluminum peelable lid. The entire contents of each tray can be dispensed intact, and one vial or pack is used each time and immediately discarded after each use.
- plastic ampules or vials or containers can be manufactured using blow-fill-seal (BFS) technology.
- BFS blow-fill-seal
- the BFS processes may involve plastic extrusion, molding, aseptic filling, and hermetic sealing in one sequential operation and those processes are known in the art.
- the formulation is packaged in multi-dose vials such that the materials can be dispensed as sterile at each time using specialized container/closure maintaining the sterility integrity.
- dispensers that incorporate unidirectional valves that allow multi-dose bottles to be unpreserved.
- the formulation is packed in conventional vials/containers as sterile product for use multiple times before discarding it.
- the invention provides methods of using the nanoemulsion for caring for cosmetic, dermatological or ophthalmological conditions.
- the formulations of the present invention are used for the treatment of or relief from various ophthalmic conditions or eye disorders.
- a method of improving or ameliorating the symptoms of ocular surface disorders is provided.
- An effective amount of the formulation of the present invention is administered topically to an eye of a subject or patient (e.g., a non-human mammal or a human) in need of the improvement or amelioration.
- An effective amount of the oil-in-water nanoemulsion is the amount sufficient to realize relief from the ocular surface disorder after the topical administration.
- the invention provides a method for improving or ameliorating the symptoms of dry eye syndrome or from contact lens use by administering the nanoemulsions disclosed herein.
- dry eye syndrome There are two major classes of dry eye syndrome: (i) aqueous tear-deficient dry eye (ADDE) and (ii) evaporative dry eye (EDE).
- ADDE aqueous tear-deficient dry eye
- EDE evaporative dry eye
- ADDE mixed mechanism dry eye
- ADDE can be further subdivided into Sjogren syndrome dry eye (where the lacrimal and salivary glands are targeted by an autoimmune process, e.g., rheumatoid arthritis) and non-Sjogren's syndrome dry eye (lacrimal dysfunction, but the systemic autoimmune features of Sjogren's syndrome are excluded, e.g., age-related dry eye).
- Sjogren syndrome dry eye where the lacrimal and salivary glands are targeted by an autoimmune process, e.g., rheumatoid arthritis
- non-Sjogren's syndrome dry eye lacrimal dysfunction, but the systemic autoimmune features of Sjogren's syndrome are excluded, e.g., age-related dry eye.
- EDE is primarily due to excessive water loss from the exposed ocular surface in the presence of normal lacrimal secretory function.
- MGD Meibomian gland dysfunction
- MGD can also accompany tear-deficient dry eye disease, as seen in ocular graft-versus-host-disease (oGVHD).
- Other specific dry eye syndromes that can be treated using compositions of the invention include keratoconjunctivitis, dry eye caused by conjunctivitis, dry eye caused by allergic conjunctivitis, dry eye caused by blepharitis, dry eye caused by keratitis, dry eye caused by dacryoadenitis, dry eye caused by ocular rosacea, dry eye caused by boehm syndrome, dry eye caused by conjunctivochalasis, dry eye caused by blepharoconjunctivitis, dry eye caused by blepharokeratoconjunctivitis, dry eye caused by superficial punctuate keratitis, dry eye caused by thygeson's superficial punctuate keratopathy, dry eye caused by oGVHD, Sjogren's dry eye syndrome, dry eye caused by Stevens-Johnson syndrome, MGD
- hormone replacement therapy blood pressure medication, antihistamine, antidepressants, anticholinergic medications, glaucoma medication, antihypertensives, diuretics, sedatives, isotretinoin, nasal decongestants, oral contraceptives, beta-blockers, phenothiazines, atropine, pain relieving opiates), pregnancy induced dry eye, LASIK surgery or refractive surgery induced dry eye, dry eye induced by collagen vascular diseases (i.e.
- the present invention provides a method of treating ocular surface abnormalities, defects, deficiencies, disorders, symptoms or diseases caused by contact lens solution or contact lens use.
- the nanoemulsions can be used for treating, improving or ameliorating the symptoms of ocular disorders including dry eye syndrome by administering to a subject (e.g., a human patient) in need of such a treatment an effective amount of a given formulation, preferably a preservative-free, sterile filtered nanoemulsion having oil globules with a median size as disclosed herein.
- a subject e.g., a human patient
- Preferred eye disorders for treatment include a dry eye syndrome (e.g., sjogren's syndrome, meibomian gland dysfunction and keratoconjunctivitis).
- the nanoemulsion is administered topically to an eye of the subject.
- nanoemulsion, formulation, nanoemulsion formulation, placebo nanoemulsion or placebo have all been used interchangeably herein, and refer to nanoemulsions of the present invention not containing any active pharmaceutical ingredient(s).
- ingredient amounts in the formulations of the present invention are presented in units of either % weight/volume (% w/v) and/or weight/weight (% w/w).
- the term “about” is not intended to limit the scope of the invention but instead encompass the specified material, parameter or step as well as those that do not materially affect the basic and novel characteristics of the invention.
- the term “about” or “approximately” as used herein refers to being within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined (e.g., the limitations of the measurement system) or the degree of precision required for a particular purpose.
- the term “about” can mean within 1 or more than 1 standard deviation, per the practice in the art.
- the term “about” when referring to a numerical value can mean ⁇ 20%, typically ⁇ 10%, often ⁇ 5% and more often ⁇ 1% of the numerical value.
- any numerical value is to be understood to be within the one standard deviation unit per the practice in the art.
- a batch of a nanoemulsion was prepared, the final composition of which is presented in Table 2 below, according to the process flow below:
- the nanoemulsion so prepared (without any active pharmaceutical ingredients added to it) was sterile filtered.
- the Viscosity of the placebo nanoemulsion prepared was 1.4 cP using Brookfield viscometer (Model-DV2TLVCJ) and Spindle (CP-52) at 20 rpm.
- the oil globules of the final nanoemulsion had a median size (Dv50) less than 100 nm. In particular, the median size was in the range of 40-80 nm. See FIG. 1 .
- NanoE Efficacy of NanoE (or ONETM) relative to a compositions containing lifitegrast (an active pharmaceutical ingredient) for the treatment of dry eye, an ocular disorder, is shown herein using an art recognized mouse model of dry eye disease (DED).
- DED dry eye disease
- the nanoemulsion administered is a preservative-free nanoemulsion.
- Commercial dry eye disease product containing lifitegrast was used for comparison.
- C57BL/6 mice were exposed to a desiccating environment combined with transdermal administration of scopolamine for a period of two weeks. Treatments were started 1 day prior to exposure to the desiccating environment and throughout dry-eye disease induction.
- Treatment groups were as follows: (a) untreated; (b) NanoE (a nanoemulsion formulation, ONE′) only without any active pharmaceutical ingredient(s); (c) Xiidra® (lifitegrast ophthalmic solution) 5% lifitegrast.
- Each of these formulations ((b)-(c)) were administered topically at 10 ⁇ L per administration per eye twice daily. Corneal surface inflammation and damage was assessed by fluorescein staining. Lacrimal gland pathology was scored by qualitative assessment of the extent of immune cell infiltration and parenchymal damage based on H&E staining. The number of goblet cells in the conjunctiva was quantified using stereological counting of PAS-stained sections.
- Nanoemulsion formulations of the present invention can be advantageously used as over-the-counter artificial tears.
- the usefulness of the formulation as over-the-counter artificial tears is an advantage of the nanoemulsion of the present invention.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
- This application is a continuation-in-part application of U.S. patent application Ser. No. 15/946,709, filed Apr. 5, 2018, and a continuation-in-part application of PCT Patent Application No. PCT/US18/26342, filed Apr. 5, 2018, both of which claim priority benefit of U.S. Provisional Application Nos. 62/509,015, filed May 19, 2017, and 62/591,548, filed Nov. 28, 2017, all of which are incorporated herein by reference in their entirety.
- The present invention relates to a sterile-filtered nanoemulsion having oil globules with a median size (Dv50) of about 100 nm or less, such as in the range of from about 40 to about 80 nm, and having an anti-inflammatory activity even in the absence of an active ingredient in the formulation. The present invention also relates to method of making the nanoemulsion and to the use of the nanoemulsion for topical application for a number of purposes in particular as an artificial tear.
- In the last decade, oil-in-water-type lipid emulsions (e.g., nanoemulsions), primarily intended for parenteral applications, have been investigated and are now being exploited as a vehicle to deliver lipophilic drug substances for cosmetic, dermatological and ophthalmological purposes. In the ophthalmological field, dry eye disease is the most actively investigated area.
- Clinicians around the world recognize the necessity to treat “dry eye patients” in a comprehensive way, taking into account their symptoms, meibomian gland physiology, tear film lipid quality and quantity, meibomian gland orifice patency, and also tear production, loss and runoff.
- Historically, dry eye disease (DED) was considered to be largely due to tear insufficiency and was treated by prescribing tear replacement products or by conserving the tears via punctal plugs. More recent treatments have included the use of methods to stimulate tears.
- Tear replacement with ocular lubricants is traditionally considered a mainstay of DED therapy and there are numerous topical formulations available. Over-the-counter (OTC) products are often termed “artificial tears” which, as their name suggests, attempt to replace and/or supplement the natural tear film (TF). Typical treatments for dry eye syndrome include (i) instillation of artificial tears for tear supplementation and stimulation and (ii) the use of anti-inflammatory drugs to reduce ocular surface inflammation. Generally, current dry eye treatment involves topical application of artificial tear products/lubricants, tear retention management, stimulation of tear secretion, topical application of antibiotics (e.g., erythromycin or bacitracin ointments), oral administration of tetracyclines (e.g., tetracycline, doxycycline, or minocycline), application of anti-inflammatory compounds (cyclosporin) and corticosteroids. These treatments are often time consuming, frustrating, and frequently ineffective or variably effective.
- The nanosize (submicron-size, i.e., <1 μm) of the oil droplets (the interfacial area available for drug exchange) creates a huge contact surface with the ocular surface cells enabling enhanced absorption. Cationorm® (CN), a cationic nanoemulsion has been reported to enhance TF stability in vivo. See Georgieve et al., 2017, Int. J. Mol. Sci., 18:1558. Such cationic emulsions were observed to have an inherent benefit on the ocular surface in terms of reduced symptoms of ocular surface even in the absence of an active ingredient. The success of the CN was attributed to the interaction between the positively charged formulation and negatively charged corneal cells. Lallemand et al., 2012, J Drug Deliv., 2012:1-16. The first marketed ophthalmic emulsion drug product was Restasis (Allergan), a preservative-free anionic emulsion of cyclosporine A (CsA) at 0.05% indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation. Other emulsion-based eye drops available on the market are artificial tears Refresh Endura (Allergan), Soothe (Bausch & Lomb), etc. Another product for treating dry eye syndrome is lifitegrast (commercially available as Xiidra®
ophthalmic solution 5%, Shire US Inc., Lexington, Mass.). Lifitegrast (chemical name: N-{[2-(1-Benzofuran-6-ylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro6-isoquinolinyl]carbonyl}-3-(methylsulfonyl)-L-phenylalanine) ophthalmic solution 5.0% has been reported to improve symptoms of ocular discomfort and eye dryness compared with placebo when administered twice daily (Sheppard et al., Ophthalmology, 2014, 121(2), pp. 475483). - Ophthalmic products, especially multidose products typically require a preservative to prevent microbial growth. The concentration of a preservative in an ophthalmic product should be a compromise between preservative efficacy and toxicity. An alternative to the preservative use could be to subject the product to sterilization process so the product is sterile. It is known in the art from Lallemand et al., 2012, J Drug Deliv., 2012:1-16) that (i) a sterilizing filtration is not possible for emulsions as it uses a filter with 0.22 μm size pores that can clog during filtration and (ii) aseptic processes are too expensive. The remaining option was heat sterilization which has its own limitations. Hence the need for a careful choice of cationic agents for nanoemulsion has emerged. These cationic agents are benzalkonium chloride, cetalkonium chloride, cetylpyridinium chloride, cetrimide and benzethonium chloride. However, these are all known preservative or antibacterial compounds.
- The need, therefore, remains for nanoemulsions which do not have the disadvantages of those of the prior art. In particular, there is a need for sterile filtered nanoemulsion formulations without active pharmaceutical ingredients in them for effective relief from various disorders including dry eye syndrome and methods for making and using such nanoemulsions.
- It has now been found that, surprisingly and unexpectedly, certain nanoemulsions even without any active pharmaceutical ingredient (“API”) in them have anti-inflammatory properties on topical application to mammals thereby making it possible to obtain ophthalmic compositions without any API's but exhibiting all the advantages of known ophthalmic API formulations, such as those described above, without their disadvantages. In some embodiments, unlike Cationorm®, the nanoemulsion formulations of the invention do not include any cations. In some instances, the nanoemulsion formulations of the invention are neutral, meaning there is no anion or cation in the nanoemulsion. Without being bound by any theory, it is believed that the nanoemulsion formulation of the invention provides observed clinical activity primarily via a lipid-lipid interaction.
- Accordingly, in an aspect, the present invention relates to an oil-in-water nanoemulsion having oil globules with a median size (Dv50) of about 100 nm or less. Preferably, the oil globules have a median size (Dv50) ranging from about 20 to about 80 nm. Still more preferably, the oil globules have a median size (Dv50) ranging from about 40 to about 60 nm. The oil-in-water nanoemulsion contains an oil, and at least one or more of emulsion stabilizing polymers, a water-soluble polymer, a surfactant, a tonicity modifier or stabilizer. The nanoemulsion is a sterile-filtered nanoemulsion and is optionally preservative-free. The nanoemulsion, even in the absence of an active ingredient, has ameliorative effects comprising anti-inflammatory activity on the ocular surface as determined by an improved corneal fluorescein staining (CFS) or CFS score compared to a therapeutic pharmaceutical composition containing lifitegrast. In one particular embodiment, an oil-in-water nanoemulsion comprises oil globules with a median size (Dv50) of about 100 nm or less. In certain instances, said nanoemulsion is a sterile-filtered nanoemulsion. Yet in other instances, the oil-in-water nanoemulsion consists essentially of an oil, an emulsion stabilizing polymer, a water soluble polymer, a surfactant, a tonicity modifier or stabilizer, a buffer, water, or a combination thereof.
- In one embodiment, the oil in the emulsion is selected from castor oil, corn oil, olive oil or oleic acid, sesame oil, soybean oil, cottonseed oil, peanut oil, safflower oil, sunflower oil, palm oil, palm kernel oil, and canola oil or a combination thereof. Preferably the oil is castor oil. Preferred surfactant is polysorbate 80, and Pemulen® used as an emulsifier. Tonicity modifier or stabilizer is selected from a polyol, a non-reducing disaccharide, and a combination thereof.
- Preferably the oil-in-water nanoemulsion contains glycerin, a polymeric emulsifier (e.g., Acrylates/C10-30 Alkyl Acrylate Cross-Polymer or Pemulen®), castor oil, a surfactant (e.g., polysorbate 80) and a buffering salt (e.g., sodium citrate dehydrate), and has a pH in the range of from about
pH 5 to about pH 8. Preferably glycerin is present at a concentration of about 2.2% w/w, the polymeric emulsifier is present at a concentration of about 0.05% w/w, castor oil is present at a concentration of about 1.25% w/w, the surfactant is present at a concentration of about 1% w/w, and the buffering salt is present at a concentration of about 0.15% w/w. Sufficient quantity of pH adjusting solutions are preferably added to prepare final nanoemulsion formulation. This final formulation is sterilized preferably by sterile filtration. - In another embodiment, the oil-in-water nanoemulsion is part of a vehicle for topically delivering a cosmetically, dermatologically or ophthalmologically active pharmaceutical agent.
- In another aspect, the present invention relates to a method of preparing the oil-in-water nanoemulsion described above. The method entails, among other steps, mixing the aqueous phase and the oil phase with vigorous stirring at a temperature ranging from about 55° C. to about 65° C., high shear mixing of the aqueous phase and the oil phase using homogenization method at a temperature ranging from about 55 to about 65° C. to realize a homogenized mixture. The homogenizing of the mixture is conducted at 3000 to 15000 rpm under high shear. The homogenized mixture is further subjected to high pressure preferably through a microfluidization method. Subjecting the homogenized mixture to a further high pressure is preferably carried out at a temperature ranging from about 55 to about 65° C. and at a pressure ranging from about 20000 to about 30000 psi.
- In another aspect, the present invention relates to a method of treating ocular surface disorders. “Treating” or “treatment” of an ocular disorder includes: (1) preventing the disease, i.e., causing the clinical symptoms of the disease not to develop in a subject that may be exposed to or predisposed to the ocular disorder but does not yet experience or display symptoms of the ocular disorder; (2) inhibiting, arresting, ameliorating, or reducing the development of the ocular disorder or its clinical symptoms; or (3) relieving the ocular disorder or the symptoms of ocular disorder, i.e., causing regression of the ocular disorder or its clinical symptoms. The method involves administering an effective amount of the oil-in-water nanoemulsion of the present invention (i.e., “NanoE” or “ONE™”) topically to an eye of a subject (e.g., a human) in need of such a treatment. In one particular embodiment, the ocular surface disorder is a dry eye syndrome.
- In another aspect, the present invention relates to an oil-in-water nanoemulsion that is sterile-filterable. The nanoemulsion is preferably preservative-free. The nanoemulsion formulation of the invention can be prepared by a process involving mixing the aqueous phase and the oil phase with vigorous stirring typically at a temperature ranging from about 55 to about 65° C., homogenizing the mixture typically at a temperature ranging from about 55 to about 65° C. at 3000-15000 rpm and subjecting the homogenized mixture to high pressure shearing typically at a pressure ranging from about 20000 to about 30000 psi to provide the oil-in-water nanoemulsion of the invention. The oil-in-water nanoemulsion so realized can optionally be filtered using a 0.22 μm filter. Typically, the oil globules in nanoemulsion formulations of the invention have a median size (Dv50) ranging from about 20 to about 80 nm, and often ranging from about 40 to about 60 nm. The sterile filtered nanoemulsion even in the absence of an active ingredient has therapeutic or ameliorative effects such as anti-inflammatory activity particularly on the ocular surface as determined by an improved corneal fluorescein staining (CFS). Surprisingly and unexpectedly, it was found that in some embodiments, the nanoemulsion formulations of the invention has anti-inflammatory activity similar to or better than a therapeutic pharmaceutical composition containing lifitegrast. As used herein, unless the context requires otherwise, the terms “active pharmaceutical ingredient” and “active ingredient” are used interchangeably herein and refers to a drug or a physiologically active compound approved or as recognized by the Food and Drug Administration (“FDA”) or a compound recognized by one skilled in the art as being an active ingredient, see for example, en.wikipedia.org/wiki/Active_ingredient. In one particular embodiment, the nanoemulsion formulations of the invention do not include any art recognized active ingredient.
- In another aspect of the invention, an artificial tear composition containing the oil-in-water nanoemulsion of the present invention and method of use of such artificial tears are provided. In an embodiment, the oil-in-water nanoemulsion by itself is used as an artificial tear in which instance the artificial tears of the invention consist of the oil-in-water nanoemulsion of the present invention. The artificial tear composition of the invention can also consist essentially of the oil-in-water nanoemulsion of the present invention, i.e., it necessarily includes the oil-in-water nanoemulsion of the present invention, and is open to other components or ingredients (exclusive of any active pharmaceutical ingredients) that do not materially affect the basic and novel properties of the artificial tear composition of the invention. Preferably, the artificial tear composition containing the oil-in-water nanoemulsion of the present invention or consisting of or consisting essentially of the oil-in-water nanoemulsion is used in a process for treating the symptoms of ocular surface disorders such as dry eye or from contact lens use. The method involves administering topically to an eye of a human subject in need of such a treatment an effective amount of the artificial tear containing, consisting of or consisting essentially of the oil-in-water nanoemulsion of the present invention.
-
FIG. 1 is a graph showing Particle Size Distribution (PSD) of nanoemulsion measured using Mastersizer 3000 instrument (Malvern, UK). -
FIG. 2A shows images depicting representative corneal fluorescein staining (CFS) scores from the mouse dry-eye disease model in the three different groups from left to right as follows: (A) untreated; (B) NanoE nanoemulsion formulation (NanoE) only; and (C) Xiidra® (lifitegrast ophthalmic solution) 5% lifitegrast. -
FIG. 2B is a histogram showing data related to the effect of placebo nanoemulsion against corneal epithelial damage in different groups as described inFIG. 2A . Data are presented as median±interquartile range. - This invention is based, at least in part, on the discovery by the present inventors that the nanoemulsions of the invention (“NanoE” or “ONE™”), even in the absence of an active pharmaceutical ingredient, have a surprising and unexpected benefit on the ocular surface in terms of, including but not limited to, its anti-inflammatory activity. In an aspect of the invention, a nanoemulsion, preferably an oil-in-water nanoemulsion with an oil phase dispersed in an aqueous phase, having an anti-inflammatory activity is provided. The nanoemulsions of the present invention are free of active pharmaceutical ingredient(s). The term “active pharmaceutical ingredient” is well known to one skilled in the art and is defined as any substance or mixture of substances intended to be used in the manufacture of a drug product and that, when used in the production of a drug, becomes an active ingredient in the drug product. The nanoemulsion of the present invention can be used as a topical ophthalmic formulation. In some embodiments, the nanoemulsion of the present invention is used as an artificial tear composition.
- The formulation necessarily contains an oil or a fatty acid ester. A fatty acid ester has the meaning commonly understood in the art, being an ester formed between an alcohol and a fatty acid. Exemplary fatty acid esters that are useful in formulations of the invention include, but are not limited to, triglyceride esters commonly known as vegetable oils, mono and diglyceride esters of fatty acids, fatty acid methyl esters, as well as other fatty acid esters that are known to one skilled in the art. It should be appreciated the fatty acid ester can be a mixture of several chemical compounds or an essentially pure compound. Typically, the fatty acid ester is a vegetable oil. Particular examples of vegetable oils that can be used include, but are not limited to, castor oil, corn oil, olive oil, oleic acid, sesame oil, soybean oil, cottonseed oil, peanut oil, safflower oil, sunflower oil, palm oil, palm kernel oil, and canola oil. Preferably the formulation contains castor oil, corn oil, olive oil, oleic acid or a combination of these components. It is particularly preferred that the fatty acid ester is castor oil. The oil phase can also contain fatty substances other than the oils indicated above, such as fatty alcohols, for example, stearyl, cetyl and behenyl alcohols, fatty acids, for example stearic, palmitic and behenic acids, oils of fluorinated type, waxes, gums and their mixtures.
- Besides an oil or a fatty acid ester, the formulation can contain a pharmaceutically acceptable excipient including an emulsion stabilizing polymer, a surfactant, a water-soluble polymer, a tonicity modifier or a stabilizer selected from the group consisting of a polyol, a non-reducing disaccharide, and a combination thereof, buffering salts, and pH adjusting acid/base solutions. While not intending to limit the scope of the invention, emulsion stabilizing polymers generally contain hydrophilic groups such as cellulose, sugars, ethylene oxide, hydroxide, carboxylic acids or other polyelectrolytes. Without being bound by any theory, it is believed that these polymers help to stabilize emulsions. Some examples of emulsion stabilizing polymers useful in this invention include, but are not limited to, carbomers, Pemulen®, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, povidone, polyethylene glycol and a mixture of two or more thereof.
- In some embodiments, Pemulen® (B.F. Goodrich, Cleveland, Ohio) is used as the polymeric emulsifier and/or nanoemulsion stabilizer. Pemulen® are Acrylates/C10-30 Alkyl Acrylate Cross-Polymers.
- A number of water-soluble polymers are known in the art. Preferably for the nanoemulsion of the present invention, the water-soluble polymer can be any of polyacrylamides, polyacrylic acids or copolymers of polyacrylic acid, polyethylene oxides, guars, hydroxyethyl celluloses, polyvinyl alcohols or mixtures thereof. Preferably, the water-soluble polymer is nonionic, that is to say neutral. Preferably, the water-soluble nonionic polymer is present in a nanoemulsion thickening effective amount.
- The formulation of this invention further contains a surfactant. Without being bound by any theory, a surfactant is used to help facilitate the formation of the emulsion and improve its stability. Any type of surfactant can be used including, anionic, amphoteric, zwitterionic, nonionic, as well as a mixture of two or more thereof. Preferably, the formulation of the invention contains an anionic or a nonionic surfactant. Exemplary nonionic surfactants include, but are not limited to, polysorbates, poloxamers, alcohol ethoxylates, ethylene glycol-propylene glycol block copolymers, fatty acid amides, alkylphenol ethoxylates, phospholipids, and two or mixture thereof. In one particular embodiment, the surfactant is Polysorbate 80. The formulation of the present invention is preferably free of any cationic surfactant or contains surfactants other than cationic surfactants. Preferably the formulation contains surfactants that are nonionic. Preferably, the nanoemulsion of the present invention containing nano-size globules contains castor oil, a surfactant-polysorbate 80, and an emulsifier-Pemulen TR2 and a tonicity agent-glycerine. Preferred formulation has the nano-size globules that are neutral at formulation pH (pH range of from about
pH 5 to about pH 8), preferably at physiological pH (e.g., pH 7.4) without any significant positive or negative surface charges. - The amount of surfactant in the nanoemulsion of the invention can range, for example, from about 0.1 to about 40 mg (i.e., 0.01% to 4% by weight) and preferably from about 0.5% to about 1% by weight with respect to the total weight of the nanoemulsion. These ranges include all specific values and subranges therebetween, such as 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 and 1.0%.
- Preferably, a tonicity agent (tonicity-adjusting agent) is used to adjust the composition of the formulation to the desired isotonic range. The tonicity-adjusting agent can be a polyol or a disaccharide including non-reducing disaccharides. Such tonicity agents are known to one skilled in the art, and include, but are not limited to, glycerin, mannitol, sorbitol, trehalose, xylitol, sodium chloride, and other electrolytes. In one particular embodiment, the tonicity agent is glycerin.
- If desired, gum and/or resin can be included in the formulations of the invention, including for example, sodium polyacrylate, cellulose ether, calcium alginate, carboxyvinyl polymer, ethylene-acrylic acid copolymer, vinyl pyrrolidone polymer, vinyl alcohol-vinyl pyrrolidone copolymer, nitrogen-substituted acrylamide polymer, polyacrylamide, cationic polymer such as cationic guar gum, dimethylacrylic ammonium polymer, acrylic acidmethacrylic acid copolymer, polyoxyethylene-polypropylene copolymer, polyvinyl alcohol, pullulan, agar, gelatine, chitosan, polysaccharide from tamarindo seed, xanthan gum, carageenan, high-methoxyl pectin, low-methoxyl pectin, guar gum, acacia gum, microcrystalline cellulose, arabinogalactan, karaya gum, tragacanth gum, alginate, albumin, casein, curdlan, gellan gum, dextran, cellulose, polyethyleneimine, high polymerized polyethylene glycol, cationic silicone polymer, synthetic latex, acrylic silicone, trimethylsiloxysilicate and fluorinated silicone resin.
- In certain embodiments, the formulations of the present invention are directed to artificial tear compositions containing combinations components but without any exogenously supplied active pharmaceutical ingredients in them (without regard to the use of transitional phrases such as “comprising” in claiming the invention herein) whereby an oil or a fatty acid ester, one or more nonionic surfactants and/or at least one excipient selected from polysorbate 80, an emulsion stabilizing polymer (e.g., Acrylates/C10-30 Alkyl Acrylate Cross-Polymer or) Pemulen®, a polyol or a combination thereof confer the desired properties of relief from ocular disorders including those from contact lens use. The present invention is based, in part, on the surprising discovery that nanoemulsion of the present invention without any added active pharmaceutical ingredients can be used as artificial tears as a first-line therapy for ocular surface disorders such as dry eye or from contact lens use. Without wishing to be bound by any theory, it is believed that the artificial tears containing nanoemulsion of the present invention improve or ameliorate the symptoms of ocular surface disorders by lubricating the ocular surface to create an evaporative tear shield that can stabilize the aqueous and lipid layers of the tear film and/or by increasing tear volume. Artificial tear compositions of the present invention also modestly confer anti-inflammatory activity on the ocular surface. The net effect of the relief provided by the artificial tear compositions of the present invention is at least as effective as, if not greater than, that provided by prescription medications such as Xiidra®
ophthalmic solution 5% made by Shire US Inc., Lexington, Mass. Artificial tears can be formulated containing the oil-in-water nanoemulsion of the present invention. Accordingly, an artificial tear composition containing, consisting essentially of or consisting of the oil-in-water nanoemulsion of the present invention is used in a method for improving or ameliorating the symptoms of ocular surface disorders such as dry eye or from contact lens use. - In another aspect, the invention provides methods of preparing the formulations of the present invention. Preferably, the formulation is a nanoemulsion. The manufacturing process involves phase mixing of the aqueous phase and the oil phase. The mixture is preferably stirred at 100-200 rpm or higher for several minutes to hours. After phase mixing is complete, the samples are subjected to high shear mixing under homogenization. The shearing preferably ranges from 3000 to 15000 rpm and at 55 to 65° C. Preferably, the high shear mixing is carried out at 3000-15000 rpm for 5-15 min depending on the manufacturing scale. High shear mixing is carried out to realize or obtain globules in the size range of <10 micron (or μ), preferably <7 micron, more often <5 micron. In order for achieving submicron sizing, preferably below 100 nm, of the oil droplets, the emulsion is put through a high-pressure microfluidization by passing the mixture through the high-pressure microfluidizer, preferably at a pressure higher than 20000 psi, at an ambient temperature of 45° C.-65° C. Preferably the high-pressure homogenization is carried out at a pressure ranging from 20000 to 30000 psi. Such a process makes it possible to obtain nanoemulsions that can be filtered through a 0.22 μm filter without clogging the sterile filter during filtration. Preferably the process results in globule mean size (Dv 50) of ≤150 nm, or ≤100 nm, or between 40-80 nm or 40-60 nm. According to Malvern Mastersizer 3000 instrument used to measure size distribution in the instant case, Dv 50 is the size in microns at which 50% of the sample is smaller and 50% is larger than this diameter. This value is also known as the Mass Median Diameter (MMD) or the median of the volume distribution. The v in the expression Dv 50 refers to the volume distribution. The viscosity can be in the range of 1-10 cP or cps when measured at ambient temperature (e.g., 25° C. or 32° C. or lower). The viscosity can be measured by any of a number of viscometers known in the art such as, for example, Brookfield viscometer (e.g., Model-DV2TLVCJ) and Spindle (e.g., CP-52) at 20 rpm. The final nanoemulsions can be filtered through a 0.22 μm filter without clogging during filtration. In some embodiments, formulations or nanoemulsions of the present invention are sterilized by filtering through a 0.22 μm filter (i.e., sterile-filtered) unless otherwise stated as sterilized by other means such as, for example, by autoclaving at about 121° C., or by gamma or e-beam irradiation, or by using antimicrobials or preservatives, etc.
- Preferably, a method of preparing the oil-in-water nanoemulsion can include mixing the aqueous phase and the oil phase with vigorous stirring at a temperature ranging from 55 to 65° C., homogenizing the mixture at a temperature ranging from 55 to 65° C. at 3000-15000 rpm under high shear and a further high pressure shearing using a microfluidizer at a much higher pressure which can range preferably from 20000 to 30000 psi. The step of homogenizing the mixture is preferably carried out at 3000-15000 rpm under high shear.
- One particular embodiment of a process flow for preparing a nanoemulsion of the invention is described below:
-
- 1. Mix Oil phase: Mix appropriate amounts of castor oil and polysorbate 80 until uniformity is obtained.
- 2. Mix Aqueous phase: Mix required amounts of Pemulen, water and glycerin until uniformity is obtained.
- 3. Perform primary mixing of oil and aqueous phase mixtures from steps 1 and 2.
- 4. Perform high shear mixing using homogenization of mixture from step 3.
- 5. Perform high-pressure microfluidization using microfluidizer.
- 6. Confirm the nanoemulsion properties via in-process testing.
- 7. Add required amount of other excipients, like glycerin, buffer salts and pH adjusting solution to prepare final nanoemulsion formulation. Perform sterile filtration.
- The above steps of the process flow need not be carried out in the same order.
- An example of a nanoemulsion with its various components (w/w) is as follows: surfactant such as Polysorbate 80 at about 0.02%-2% by weight or poloxamer/tyloxapol at about 0.1% and 0.25% by weight; carbomer copolymer (type A or type B) about 0.05% by weight; tonicity agent (glycerine or includes glycerine about 2.2% by weight; citrate/tris buffer of pH 6.0-8.0, sodium EDTA in the amount of about 0.02% or less by weight; an oil (e.g., castor oil) in the amount of about 1.25% by weight. Alternatively, the oil for the oil phase is a medium chain triglyceride in the range from 0.5-4%, typically at about 2%. To prepare this formulation, all water-soluble components can be added and heated (about 60-70° C.) to make water the phase with buffer. A lipophilic solution is prepared using a lipophilic solvent (e.g., castor oil) and heating to about 60-70° C. The nanoemulsion is formed by rapid addition of lipophilic solution into water phase followed by high shear mixing. The final solution is sterilized via 0.22 micron filter. Alternatively, sterilization can also be done by autoclaving at about 121° C. for 20 min. Alternatively, sterilization can also be done by gamma or e beam irradiation. The sterilized nanoemulsion is filled into single dose disposable tubes by BFS technology or the like or into multi-dose container/closure systems (further described elsewhere herein). The formulation can be used topically, for caring for cosmetic, dermatological or ophthalmological conditions. Preferably, this and other compositions described throughout the disclosure herein can be used for treating an eye disorder (e.g., dry eye syndrome) or alleviating the symptoms of the eye disorder or as an artificial tear composition.
- Yet another example of the present invention formulation with its various components (w/w) is as follows. This particular formulation includes carbomer homopolymer type B in an amount ranging from about 0.2% to about 0.6%, by weight typically in an amount of about 0.4% or about 0.25%, and/or carbomer homopolymer type C in an amount ranging from about 0.4 to about 5% typically in an amount of about 4% or about 2.5%, and/or polycarbophil in an amount ranging from about 0.2% to about 0.5% typically in an amount of about 0.4% or about 0.2%; glycerin in an amount ranging from about 0.5% to about 1% typically in an amount of about 0.9%; optionally, benzalkonium chloride in an amount ranging from about 0.003% to about 0.01% typically in an amount of about 0.007%; edetate sodium in an amount ranging from about 0.03% to about 0.07% typically in an amount of about 0.05%; sodium chloride in an amount of up to about 0.09%, typically in an amount of about 0.06% or q.s. to isotonicity, or mannitol q.s. to isotonicity, or without isotonicity adjustors sodium chloride and mannitol; propylene glycol in an amount ranging from about 0.3% to about 0.6% typically in an amount of about 0.5%; water q.s., to 100 g and sodium hydroxide or hydrochloric acid q.s., to adjust pH to 7.8. Although preservatives such as benzalkonium chloride can be used in the formulations of the present invention as described in the non-limiting examples, the formulations of the present invention are preferably preservative-free unless stated otherwise. In the context of the present invention, a “preservative” is a substance or a chemical that is added to products such as pharmaceutical and dermatological products and cosmetics and many other products in an attempt to prevent decomposition by microbial growth or by undesirable chemical changes. The term “preservative-free” used in connection with the nanoemulsions of the present invention refers to the formulations free of preservatives including benzalkonium chloride, cetalkonium chloride, cetylpyridinium chloride, cetrimide and benzethonium chloride and such other known preservatives. The formulation can be used topically, for caring for cosmetic, dermatological or ophthalmological conditions. Preferably, it can be used for treating an eye disorder (e.g., dry eye syndrome) or alleviating the symptoms of the eye disorder or as an artificial tear composition.
- Another example of a formulation with its various components (w/w) is as follows: a surfactant such as Polysorbate 80 at about 0.02%-2% by weight or carbomer copolymer (type A or type B) about 0.05% by weight; tonicity agent (glycerine or includes glycerine about 2.2% by weight; sodium citrate and tris buffer of pH 6.0-8.0, sodium EDTA in the amount of about 0.02% or less by weight; an oil (e.g., castor oil) in the amount of about 1.25% by weight.
- Another example of a formulation with its various components (w/w) is as follows: a surfactant such as Polysorbate 80 at about 0.02%-2% by weight; carbomer copolymer (type A or type B) about 0.05% by weight; tonicity agent (glycerin or includes glycerin about 2.2% by weight; sodium citrate and tris buffer of pH 6.0-8.0; an oil (e.g., castor oil) in the amount of about 1.25% by weight, and acid/base solution to adjust the pH.
- Yet another example of a formulation with its various components (w/w) is as follows: Carbopol 971 at about 0.1% to 0.4% by weight, poloxamer/tyloxapol at about 0.1% and 0.3% by weight; tonicity agent (glycerin or includes glycerin about 1% to 3% by weight; sodium citrate and tris buffer of pH 6.0-8.0; sodium EDTA in the amount of about 0.02% or less by weight.
- Still another example of a formulation with its various components (w/w) is as follows: povidone at about 0.6% by weight, poloxamer/tyloxapol at about 0.1% and 0.25% by weight; tonicity agent (glycerine or includes glycerine about 1 to 3% by weight; sodium citrate and tris buffer of pH 6.0-8.0; sodium EDTA in the amount of about 0.02% or less by weight.
- Still yet in another example, the oil-in-water nanoemulsion contains glycerin, a polymeric emulsifier (e.g., Acrylates/C10-30 Alkyl Acrylate Cross-Polymer or Pemulen®), castor oil, a surfactant (e.g., polysorbate 80) and a buffering salt (e.g., sodium citrate dehydrate), and has a pH of 5 to 8. Preferably glycerin is present at a concentration of about 2.2% w/w, the polymeric emulsifier is present at a concentration of about 0.05% w/w, castor oil is present at a concentration of about 1.25% w/w, the surfactant is present at a concentration of about 1% w/w, and the buffering salt is present at a concentration of about 0.15% w/w. In addition, a small amount of Tris base (at about 0.03% w/w) can be present. The pH of the nanoemulsion can be adjusted using preferably HCl 0.1N and/or NaOH 0.1N as required. Water for injection q.s. is added.
- One particular nanoemulsion formulation composition is shown in Table 1 below.
-
TABLE 1 An example of the composition of the invention. Ingredient Range per g Per g Other substitutes Function Castor Oil 5-100 mg 12.5 mg Olive oil, Oleic acid, etc. Oil Phase Polysorbate 0.1 to 40 mg 10 mg Polysorbate-20, A component to both help 80 Poloxamer 188 facilitate the formation of the heterogeneous mixture and improve its stability. Pemulen TR-2 0.1 to 2 mg 0.5 mg N/A Emulsion Stabilizer Glycerin 0-100 mg 22 mg Trehalose, sorbitol, Tonicity-Adjusting Agent mannitol, xylitol Sodium 0-20 mg 1.47 mg Phosphate, tris, histidine, Maintain pH Citrate acetate, succinate Dihydrate Tris Base 0-15 mg 1 mg Maintain pH Preservative Optional Optional benzalkonium chloride For multidose and nonsterile (BAK), stabilized products oxychloro complex (Purite) Base for pH pH 5 to 8 Maintain pH Acid for pH pH 5 to 8 Maintain pH Water for q.s. Vehicle Injection - The physical stability of these exemplary nanoemulsion formulations can be monitored. For example, the formulations are allowed to stand for a period of time (e.g., 6 months) at 20 to 25° C., and the heterogeneity sizes are measured. The heterogeneity sizes, within experimental error, should be identical at end of the test period to those measured right after the nanoemulsion is prepared thereby suggesting that there is no significant coalescence of the heterogeneity. Such results demonstrate that the nanoemulsion formulations so prepared have superior physical stability.
- A nanoemulsion formulation of the present invention can be a finished dosage form that does not contain an active ingredient. Preferably, the dosage form of the invention is eye drops of the nanoemulsion formulations. The formulations of the present invention can be packaged in various package forms known in the field of topical ophthalmic. The formulations can be packaged in sterile single-use (unit dose) or multi-dose vials, preservative-free. In one embodiment, the formulation is packaged in sterile, preservative-free single-use packs or vials or containers (i.e., the unit dose vials). Each vial, for example as small as a 0.9 mL, may be made of low-density polyethylene so as to contain a small quantity of the formulation, e.g., 0.1-0.4 mL for a single use. This way, where the pharmaceutical composition is sterilized and contained in disposable single-dose containers for topical use in drop form, multiple vials in the form of a set of 30 vials, 60 vials and so on can be packaged in a tray with a lid, for example, a polypropylene tray with an aluminum peelable lid. The entire contents of each tray can be dispensed intact, and one vial or pack is used each time and immediately discarded after each use. For example, plastic ampules or vials or containers can be manufactured using blow-fill-seal (BFS) technology. The BFS processes may involve plastic extrusion, molding, aseptic filling, and hermetic sealing in one sequential operation and those processes are known in the art. In another embodiment, the formulation is packaged in multi-dose vials such that the materials can be dispensed as sterile at each time using specialized container/closure maintaining the sterility integrity. A number of new products are now available that utilize dispensers that incorporate unidirectional valves that allow multi-dose bottles to be unpreserved. In yet another embodiment, the formulation is packed in conventional vials/containers as sterile product for use multiple times before discarding it.
- In another aspect, the invention provides methods of using the nanoemulsion for caring for cosmetic, dermatological or ophthalmological conditions. Preferably, the formulations of the present invention are used for the treatment of or relief from various ophthalmic conditions or eye disorders. In some embodiments, a method of improving or ameliorating the symptoms of ocular surface disorders is provided. An effective amount of the formulation of the present invention is administered topically to an eye of a subject or patient (e.g., a non-human mammal or a human) in need of the improvement or amelioration. An effective amount of the oil-in-water nanoemulsion is the amount sufficient to realize relief from the ocular surface disorder after the topical administration.
- In particular, the invention provides a method for improving or ameliorating the symptoms of dry eye syndrome or from contact lens use by administering the nanoemulsions disclosed herein. There are two major classes of dry eye syndrome: (i) aqueous tear-deficient dry eye (ADDE) and (ii) evaporative dry eye (EDE). There are also cases of mixed mechanism dry eye (i.e., both ADDE and EDE). ADDE is primarily due to failure of lacrimal tear secretion. ADDE can be further subdivided into Sjogren syndrome dry eye (where the lacrimal and salivary glands are targeted by an autoimmune process, e.g., rheumatoid arthritis) and non-Sjogren's syndrome dry eye (lacrimal dysfunction, but the systemic autoimmune features of Sjogren's syndrome are excluded, e.g., age-related dry eye). In contrast, EDE is primarily due to excessive water loss from the exposed ocular surface in the presence of normal lacrimal secretory function. Its causes can be extrinsic (e.g., ocular surface disorder due to some extrinsic exposure, contact lens wear or vitamin A deficiency) or intrinsic (e.g., Meibomian gland dysfunction and disorders of eyelid aperture). Meibomian glands secrete a mixture of lipids and other components that form the outer layer of the preocular tear film. This lipid layer functions to decrease tear film evaporation. Meibomian gland dysfunction (MGD) leads to evaporative dry eye disease. One of the most well-recognized clinic finding in MGD is the presence of numerous telangiectatic blood vessels coursing across the eyelid margin. MGD can also accompany tear-deficient dry eye disease, as seen in ocular graft-versus-host-disease (oGVHD). Other specific dry eye syndromes that can be treated using compositions of the invention include keratoconjunctivitis, dry eye caused by conjunctivitis, dry eye caused by allergic conjunctivitis, dry eye caused by blepharitis, dry eye caused by keratitis, dry eye caused by dacryoadenitis, dry eye caused by ocular rosacea, dry eye caused by boehm syndrome, dry eye caused by conjunctivochalasis, dry eye caused by blepharoconjunctivitis, dry eye caused by blepharokeratoconjunctivitis, dry eye caused by superficial punctuate keratitis, dry eye caused by thygeson's superficial punctuate keratopathy, dry eye caused by oGVHD, Sjogren's dry eye syndrome, dry eye caused by Stevens-Johnson syndrome, MGD, dry eye caused by meibomian gland disease, vitamin A deficiency induced dry eye, pharmacological induced dry eye (i.e. hormone replacement therapy, blood pressure medication, antihistamine, antidepressants, anticholinergic medications, glaucoma medication, antihypertensives, diuretics, sedatives, isotretinoin, nasal decongestants, oral contraceptives, beta-blockers, phenothiazines, atropine, pain relieving opiates), pregnancy induced dry eye, LASIK surgery or refractive surgery induced dry eye, dry eye induced by collagen vascular diseases (i.e. systemic lupus erythematosus, Wegener's granulomatosis, rheumatoid arthritis, relapsing polychondritis), dry eye caused by the infiltration of the lacrimal glands by tumors or sarcoidosis, dry eye caused by postradiation fibrosis of tear producing glands, dry eye caused by lacrimal gland, meibomian gland, or goblet cell ablation, dry eye caused by sensory denervation, dry eye caused by thermal or chemical burns, dry eye caused by underlying diabetic conditions, dry eye caused by viral, fungal, or bacterial infection, dry eye caused by prolonged contact lens use, dry eye caused by eyelid disorders or injury to the eyelid (i.e. bulging eyes, drooping eyelid), dry eye caused by corneal dystrophy, dry eye caused by autoimmune disorders, age-induced dry eye, and a combination thereof. Preferably, the present invention provides a method of treating ocular surface abnormalities, defects, deficiencies, disorders, symptoms or diseases caused by contact lens solution or contact lens use.
- The nanoemulsions can be used for treating, improving or ameliorating the symptoms of ocular disorders including dry eye syndrome by administering to a subject (e.g., a human patient) in need of such a treatment an effective amount of a given formulation, preferably a preservative-free, sterile filtered nanoemulsion having oil globules with a median size as disclosed herein. Preferred eye disorders for treatment include a dry eye syndrome (e.g., sjogren's syndrome, meibomian gland dysfunction and keratoconjunctivitis). Preferably, the nanoemulsion is administered topically to an eye of the subject.
- The terms nanoemulsion, formulation, nanoemulsion formulation, placebo nanoemulsion or placebo have all been used interchangeably herein, and refer to nanoemulsions of the present invention not containing any active pharmaceutical ingredient(s). Unless otherwise specified, the ingredient amounts in the formulations of the present invention are presented in units of either % weight/volume (% w/v) and/or weight/weight (% w/w). As used herein, the term “about” is not intended to limit the scope of the invention but instead encompass the specified material, parameter or step as well as those that do not materially affect the basic and novel characteristics of the invention. When referring to a numeric value, the term “about” or “approximately” as used herein refers to being within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined (e.g., the limitations of the measurement system) or the degree of precision required for a particular purpose. For example, the term “about” can mean within 1 or more than 1 standard deviation, per the practice in the art. Alternatively, the term “about” when referring to a numerical value can mean±20%, typically ±10%, often ±5% and more often ±1% of the numerical value. In general, however, where particular values are described in the application and claims, unless otherwise stated, the term “about” means within an acceptable error range for the particular value. Moreover, any numerical value is to be understood to be within the one standard deviation unit per the practice in the art.
- Additional objects, advantages, and novel features of this invention will become apparent to those skilled in the art upon examination of the following examples thereof, which are not intended to be limiting. In the Examples, procedures that are constructively reduced to practice are described in the present tense, and procedures that have been carried out in the laboratory are set forth in the past tense.
- A batch of a nanoemulsion was prepared, the final composition of which is presented in Table 2 below, according to the process flow below:
-
- 1. Oil phase: Mixed appropriate amounts of castor oil and polysorbate 80 until uniformity is obtained.
- 2. Aqueous phase: Mixed required amounts of Pemulen, water and glycerin until uniformity is obtained
- 3. Performed primary mixing of oil and aqueous phase mixtures from steps 1 and 2 understirring at 100-200 rpm for several minutes.
- 4. Performed high shear mixing at 3000-15000 rpm for 5-15 min depending on the manufacturing scale and at temperature of between 55-65° C.
- 5. Perform high-pressure microfludization of mixture from step 4 at 20000-30000 psi at a temperature of about 55-65° C.
- 6. Formulate nanoemulsion with other excipients like stabilizer, tonicity modifiers, buffer salts and pH adjusting solutions.
- 7. Perform sterile filtration and Confirm the ophthalmic solution properties via in-process testing
- The nanoemulsion so prepared (without any active pharmaceutical ingredients added to it) was sterile filtered. The Viscosity of the placebo nanoemulsion prepared was 1.4 cP using Brookfield viscometer (Model-DV2TLVCJ) and Spindle (CP-52) at 20 rpm. The oil globules of the final nanoemulsion had a median size (Dv50) less than 100 nm. In particular, the median size was in the range of 40-80 nm. See
FIG. 1 . -
TABLE 2 Final Composition of an exemplary nanoemulsion formulation (NanoE) Raw Material Manufacturer For 1 Kg Glycerin Vegetable, P&G (Superol KPO) 22 g USP/EP Pemulen TR-2, NF Lubrizol 0.5 g Castor Oil, USP/EP Croda JSJ0470 12.5 g Polysorbate 80, NF/EP Croda SD43361 10 g Sodium Citrate Millipore - Sigma 1.47 g Dihydrate, USP/EP Aldrich Tris Base, USP/EP Millipore - Sigma 0.3 g Aldrich HCl, 0.1N Avantor As Required to pH adjust NaOH, 0.1N Avantor As Required to pH adjust Water for Injection, TRC As Required to q.s. USP/EP - Efficacy of NanoE (or ONE™) relative to a compositions containing lifitegrast (an active pharmaceutical ingredient) for the treatment of dry eye, an ocular disorder, is shown herein using an art recognized mouse model of dry eye disease (DED). The nanoemulsion administered is a preservative-free nanoemulsion. Commercial dry eye disease product containing lifitegrast was used for comparison.
- For the treatment, C57BL/6 mice were exposed to a desiccating environment combined with transdermal administration of scopolamine for a period of two weeks. Treatments were started 1 day prior to exposure to the desiccating environment and throughout dry-eye disease induction.
- Treatment groups were as follows: (a) untreated; (b) NanoE (a nanoemulsion formulation, ONE′) only without any active pharmaceutical ingredient(s); (c) Xiidra® (lifitegrast ophthalmic solution) 5% lifitegrast. Each of these formulations ((b)-(c)) were administered topically at 10 μL per administration per eye twice daily. Corneal surface inflammation and damage was assessed by fluorescein staining. Lacrimal gland pathology was scored by qualitative assessment of the extent of immune cell infiltration and parenchymal damage based on H&E staining. The number of goblet cells in the conjunctiva was quantified using stereological counting of PAS-stained sections.
FIGS. 2A and 2B show representative fluorescein staining scores. The NanoE group was comparable to the commercial lifitegrast and had improved response compared to untreated control. Fluorescein score is proportional to the level of ocular surface inflammation. These results were unexpected. Nanoemulsion formulations of the present invention can be advantageously used as over-the-counter artificial tears. The usefulness of the formulation as over-the-counter artificial tears is an advantage of the nanoemulsion of the present invention. - The foregoing discussion of the invention has been presented for purposes of illustration and description. The foregoing is not intended to limit the invention to the form or forms disclosed herein. Although the description of the invention has included description of one or more embodiments and certain variations and modifications, other variations and modifications are within the scope of the invention, e.g., as may be within the skill and knowledge of those in the art, after understanding the present disclosure. It is intended to obtain rights which include alternative embodiments to the extent permitted, including alternate, interchangeable and/or equivalent structures, functions, ranges or steps to those claimed, whether or not such alternate, interchangeable and/or equivalent structures, functions, ranges or steps are disclosed herein, and without intending to publicly dedicate any patentable subject matter. All references cited herein are incorporated by reference in their entirety.
Claims (20)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/963,955 US20180333357A1 (en) | 2017-05-19 | 2018-04-26 | Nanoemulsions with anti-inflammatory activity |
US16/116,872 US20190008920A1 (en) | 2017-05-19 | 2018-08-29 | Ophthalmic compositions and methods of use |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762509015P | 2017-05-19 | 2017-05-19 | |
US201762591548P | 2017-11-28 | 2017-11-28 | |
PCT/US2018/026342 WO2018212846A1 (en) | 2017-05-19 | 2018-04-05 | Ophthalmic compositions and methods of use |
US15/946,709 US10555947B2 (en) | 2017-05-19 | 2018-04-05 | Ophthalmic compositions and methods of use |
US15/963,955 US20180333357A1 (en) | 2017-05-19 | 2018-04-26 | Nanoemulsions with anti-inflammatory activity |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/946,709 Continuation-In-Part US10555947B2 (en) | 2017-05-19 | 2018-04-05 | Ophthalmic compositions and methods of use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/116,872 Continuation-In-Part US20190008920A1 (en) | 2017-05-19 | 2018-08-29 | Ophthalmic compositions and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180333357A1 true US20180333357A1 (en) | 2018-11-22 |
Family
ID=64270380
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/963,955 Pending US20180333357A1 (en) | 2017-05-19 | 2018-04-26 | Nanoemulsions with anti-inflammatory activity |
Country Status (1)
Country | Link |
---|---|
US (1) | US20180333357A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10980745B2 (en) * | 2019-06-11 | 2021-04-20 | Sifi S.P.A. | Microemulsion compositions |
WO2022084739A1 (en) * | 2020-10-21 | 2022-04-28 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9364461B2 (en) * | 2006-12-21 | 2016-06-14 | Santen Sas | Process for manufacturing ophthalmic oil-in-water emulsions |
-
2018
- 2018-04-26 US US15/963,955 patent/US20180333357A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9364461B2 (en) * | 2006-12-21 | 2016-06-14 | Santen Sas | Process for manufacturing ophthalmic oil-in-water emulsions |
Non-Patent Citations (2)
Title |
---|
Gupta et al, Soft Matter 2016, Vol 12, pp.2826-2841. (Year: 2016) * |
Muirhead, Ben, Ophthalmic Biomaterials 2017, pp.1-168. (Year: 2017) * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10980745B2 (en) * | 2019-06-11 | 2021-04-20 | Sifi S.P.A. | Microemulsion compositions |
US11672760B2 (en) | 2019-06-11 | 2023-06-13 | Sifi S.P.A. | Microemulsion compositions |
WO2022084739A1 (en) * | 2020-10-21 | 2022-04-28 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018212955A1 (en) | Nanoemulsions with anti-inflammatiory activity | |
Almeida et al. | In situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations | |
Sahoo et al. | Nonionic surfactant vesicles in ocular delivery: innovative approaches and perspectives | |
US20210085603A1 (en) | Microemulsion for opthalmic drug delivery | |
Aldrich et al. | Ophthalmic preparations | |
EP3409268A1 (en) | Omega-3 oil containing ophthalmic emulsions | |
US11951153B2 (en) | Topical cyclosporine-containing formulations and uses thereof | |
WO2016138049A1 (en) | Methods and compositions for treating dry eye disease and other eye disorders | |
US9801899B2 (en) | Artificial tear emulsion | |
US20210145925A1 (en) | Method of treating ophthalmic conditions | |
KR20100072333A (en) | Non-aqueous water-miscible materials as vehicles for drug delivery | |
US20190008920A1 (en) | Ophthalmic compositions and methods of use | |
CN103142462B (en) | Brinzolamide eye-drops preparations and its production and use | |
US20180333357A1 (en) | Nanoemulsions with anti-inflammatory activity | |
WO2020178429A1 (en) | Ophthalmic composition for treating dry eye and symptoms thereof | |
US20240041974A1 (en) | Nanoemulsion ophthalmic composition comprising cyclosporine and menthol, and preparation method thereof | |
JPWO2018074421A1 (en) | Ophthalmic agent and ophthalmic drug | |
US20180153885A1 (en) | Preservative free ocular compositions and methods for using the same for treating dry eye disease and other eye disorders | |
WO2020240451A1 (en) | In-situ gelling nanoemulsion of brinzolamide | |
CA3115664A1 (en) | Ophthalmic compositions and methods of use | |
Bandyopadhyay et al. | Development of ophthalmic formulations | |
US20180221278A1 (en) | Prsustained release opthalmic formuation and methods for using the same | |
Bisen et al. | Pharmaceutical Emulsions: A Viable Approach for Ocular Drug Delivery | |
Sarkar et al. | Development of Ophthalmic Formulations | |
WO2023152644A1 (en) | Pharmaceutical composition of lifitegrast and loteprednol etabonate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: OCUGEN, INC., PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ARUMUGHAM, RASAPPA, DR.;UPADHYAY, ARUN K.;REEL/FRAME:045735/0955 Effective date: 20180507 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
AS | Assignment |
Owner name: HB FUND LLC, AS COLLATERAL AGENT, NEW YORK Free format text: ASSIGNMENT OF SECURITY INTEREST - PATENTS;ASSIGNOR:OCUGEN, INC.;REEL/FRAME:049248/0209 Effective date: 20190521 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: AWAITING RESPONSE FOR INFORMALITY, FEE DEFICIENCY OR CRF ACTION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |